MSMaria Stella Sasso

Maria Stella Sasso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Stella Sasso has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffrey A. Hubbell

    Departments of Chemical and Biomolecular Engineering and of Biomedical Engineering, New York University, New York, NY, USA, 11021

    2 shared publications
  • Melody A. Swartz

    Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, 60637, United States; Committee on Immunology, University of Chicago, Chicago, IL, 60637, United States; Committee on Cancer Biology, University of Chicago, Chicago, IL, 60637, United States; Ben May Department of Cancer Research, University of Chicago, Chicago, IL, 60637, United States

    2 shared publications
  • Nikolaos Mitrousis

    Pritzker School of Molecular Engineering, University of Chicago; Chicago, IL 60637, United States

    2 shared publications
  • Priscilla S. Briquez

    Pritzker School of Molecular Engineering, University of Chicago; Chicago, IL 60637, United States

    2 shared publications
  • Aaron T. Alpar

    Pritzker School of Molecular Engineering, University of Chicago, Chicago, USA

    1 shared publication
  • Andrew C. Tremain

    University of Chicago

    1 shared publication

Latest Publications

  • Open Access

    Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant

    by Laura T. Gray, Michal M. Raczy, Priscilla S. Briquez, Tiffany M. Marchell, Aaron T. Alpar, Rachel P. Wallace, Lisa R. Volpatti, Maria Stella Sasso, Shijie Cao, Mindy Nguyen, et al.

    The SARS-CoV-2 virus has caused an unprecedented global crisis, and curtailing its spread requires an effective vaccine which elicits a diverse and robust immune response. We have previously shown that vaccines made of a polymeric glyco-adjuvant conjugated to an antigen were effective in triggering such a response in other disease models and hypothesized that the technology could be adapted to create an effective vaccine against SARS-CoV-2. The core of the vaccine platform is the copolymer p(Man-TLR7), composed of monomers with pendant mannose or a toll-like receptor 7 (TLR7) agonist. Thus, p(Man-TLR7) is designed to target relevant antigen-presenting cells (APCs) via mannose-binding receptors and then activate TLR7 upon endocytosis. The p(Man-TLR7) construct is amenable to conjugation to protein antigens such as the Spike protein of SARS-CoV-2, yielding Spike-p(Man-TLR7). Here, we demonstrate Spike-p(Man-TLR7) vaccination elicits robust antigen-specific cellular and humoral responses in mice. In adult and elderly wild-type mice, vaccination with Spike-p(Man-TLR7) generates high and long-lasting titers of anti-Spike IgGs, with neutralizing titers exceeding levels in convalescent human serum. Interestingly, adsorbing Spike-p(Man-TLR7) to the depot-forming adjuvant alum, amplified the broadly neutralizing humoral responses to levels matching those in mice vaccinated with formulations based off of clinically-approved adjuvants. Additionally, we observed an increase in germinal center B cells, antigen-specific antibody secreting cells, activated T follicular helper cells, and polyfunctional Th1-cytokine producing CD4 + and CD8 + T cells. We conclude that Spike-p(Man-TLR7) is an attractive, next-generation subunit vaccine candidate, capable of inducing durable and robust antibody and T cell responses.

  • Open Access

    Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas

    by Maria Stella Sasso, Nikolaos Mitrousis, Yue Wang, Priscilla S. Briquez, Sylvie Hauert, Jun Ishihara, Jeffrey A. Hubbell, Melody A. Swartz

    New approach for immune cell recruitment in therapeutic anticancer vaccines drives antigenically broad and long-lasting immunity.